
Novartis has gained EU approval for everolimus to be used to treat a rare non-cancerous tumour. Everolimus is already marketed …
Novartis’ novel cancer drug Votubia has reduced the size of SEGA brain tumours in a late-stage trial. Votubia (or everolimus …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

